It regulates glucose homeostasis and energy balance by slowing gastric emptying, suppressing postprandial glucagon secretion, and reducing food intake through central nervous system effects
And for those successfully using a currently available GLP-1 with success, there is no clinical reason to switch to retatrutide via a clinical trial right now
Health Canada has issued parallel advisories on unauthorized injectable peptide products, and no AOD-9604 preparation is authorized for compounding in Canada either
Key Takeaways Cagrilintide is a long-acting amylin analogue typically dosed at 2.4 mg weekly in clinical trials, working through distinct pathways from GLP-1 receptor agonists Tirzepatide follows a gradual escalation protocol from 2.5 mg to 15 mg weekly as a dual GIP/GLP-1 receptor agonist No approved combination of cagrilintide with tirzepatide currently exists, though the concept represents theoretical triple-pathway metabolic modulation Gastrointestinal side effects require careful monitoring when considering any combination of these peptides due to overlapping mechanisms Clinical evidence for cagrilintide combinations exists primarily with semaglutide, showing 15-17% body weight reductions in phase 3 trials Understanding Cagrilintide: The Amylin Analogue Cagrilintide represents a breakthrough in amylin-based therapeutics, developed by Novo Nordisk as a long-acting analogue of the naturally occurring hormone amylin[1]
[DOI] [PubMed] [Google Scholar] 160
.webp)
